Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis

World Journal of Gastroenterology

Volumn 18, Issue 37, 2012, Pages 5211-5218

  Heinzow, Hauke S ^a   Lenz, Philipp ^a   Köhler, Michael ^a   Reinecke, Frank ^a   Ullerich, Hansjörg ^a   Domschke, Wolfram ^a   Domagk, Dirk ^a   Meister, Tobias ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Department of Medicine II   (Germany)

Author keywords

Ascites; Gastrointestinal hemorrhage; Liver cirrhosis; Transjugular intrahepatic portosystemic stent shunt; Treatment outcome

Indexed keywords

ADULT; ARTICLE; ASCITES; BARE METAL STENT; BLEEDING; FEMALE; HUMAN; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PREDICTOR VARIABLE; RETROSPECTIVE STUDY; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VASCULAR PATENCY;

EID: 84867800372     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i37.5211     Document Type: Article

References (52)

1. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371: 838-851
2. de Franchis R, Dell'Era A, Iannuzzi F. Diagnosis and treatment of portal hypertension. Dig Liver Dis 2004; 36: 787-798
3. Garcia-Tsao G. Current management of the complications of cirrhosis and portal hypertension: variceal hemorrhage, ascites, and spontaneous bacterial peritonitis. Gastroenterology 2001; 120: 726-748
4. Ginès P, Cárdenas A, Arroyo V, Rodés J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646-1654
5. Ginès P, Guevara M, Arroyo V, Rodés J. Hepatorenal syndrome. Lancet 2003; 362: 1819-1827
6. Colapinto RF, Stronell RD, Gildiner M, Ritchie AC, Langer B, Taylor BR, Blendis LM. Formation of intrahepatic portosystemic shunts using a balloon dilatation catheter: preliminary clinical experience. AJR Am J Roentgenol 1983; 140: 709-714
7. Gordon JD, Colapinto RF, Abecassis M, Makowka L, Langer B, Blendis LM, Taylor B, Stronell RD. Transjugular intrahepatic portosystemic shunt: a nonoperative approach to life-threatening variceal bleeding. Can J Surg 1987; 30: 45-49
8. Richter GM, Noeldge G, Palmaz JC, Roessle M. The transjugular intrahepatic portosystemic stent-shunt (TIPSS): results of a pilot study. Cardiovasc Intervent Radiol 1990; 13: 200-207
9. Boyer TD, Haskal ZJ. The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in the Management of Portal Hypertension: update 2009. Hepatology 2010; 51: 306
10. Colombato L. The role of transjugular intrahepatic portosystemic shunt (TIPS) in the management of portal hypertension. J Clin Gastroenterol 2007; 41 Suppl 3: S344-S351
11. Forrest EH, Stanley AJ, Redhead DN, McGilchrist AJ, Hayes PC. Clinical response after transjugular intrahepatic portosystemic stent shunt insertion for refractory ascites in cirrhosis. Aliment Pharmacol Ther 1996; 10: 801-806
12. Ochs A, Rössle M, Haag K, Hauenstein KH, Deibert P, Siegerstetter V, Huonker M, Langer M, Blum HE. The transjugular intrahepatic portosystemic stent-shunt procedure for refractory ascites. N Engl J Med 1995; 332: 1192-1197
13. Rössle M, Haag K, Blum HE. The transjugular intrahepatic portosystemic stent-shunt: a review of the literature and own experiences. J Gastroenterol Hepatol 1996; 11: 293-298
14. Feyssa E, Ortiz J, Grewal K, Azhar A, Parsikia A, Tufail K, Hashemi N, Brady P, Araya V. MELD score less than 15 predicts prolonged survival after transjugular intrahepatic portosystemic shunt for refractory ascites after liver transplantation. Transplantation 2011; 91: 786-792
15. Maleux G, Perez-Gutierrez NA, Evrard S, Mroue A, Le Moine O, Laleman W, Nevens F. Covered stents are better than uncovered stents for transjugular intrahepatic portosystemic shunts in cirrhotic patients with refractory ascites: a retrospective cohort study. Acta Gastroenterol Belg 2010; 73: 336-341
16. Moore KP, Aithal GP. Guidelines on the management of ascites in cirrhosis. Gut 2006; 55 Suppl 6: vi1-v12
17. Narahara Y, Kanazawa H, Fukuda T, Matsushita Y, Harimoto H, Kidokoro H, Katakura T, Atsukawa M, Taki Y, Kimura Y, Nakatsuka K, Sakamoto C. Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol 2011; 46: 78-85
18. Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 2007; 133: 825-834
19. Anderson CL, Saad WE, Kalagher SD, Caldwell S, Sabri S, Turba UC, Matsumoto AH, Angle JF. Effect of transjugular intrahepatic portosystemic shunt placement on renal function: a 7-year, single-center experience. J Vasc Interv Radiol 2010; 21: 1370-1376
20. Luca A, Miraglia R, Caruso S, Milazzo M, Sapere C, Maruzzelli L, Vizzini G, Tuzzolino F, Gridelli B, Bosch J. Shortand long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut 2011; 60: 846-852
21. Perarnau JM, Baju A, D'alteroche L, Viguier J, Ayoub J. Feasibility and long-term evolution of TIPS in cirrhotic patients with portal thrombosis. Eur J Gastroenterol Hepatol 2010; 22: 1093-1098
22. Garcia-Pagán JC, Heydtmann M, Raffa S, Plessier A, Murad S, Fabris F, Vizzini G, Abraldes JG, Olliff S, Nicolini A, Luca A, Primignani M, Janssen HL, Valla D, Elias E, Bosch J. TIPS for Budd-Chiari syndrome: long-term results and prog-nostics factors in 124 patients. Gastroenterology 2008; 135: 808-815
23. Fanelli F, Angeloni S, Salvatori FM, Marzano C, Boatta E, Merli M, Rossi P, Attili AF, Ridola L, Cerini F, Riggio O. Transjugular intrahepatic portosystemic shunt with expanded-polytetrafuoroethylene-covered stents in non-cirrhotic patients with portal cavernoma. Dig Liver Dis 2011; 43: 78-84
24. Boyer TD. Transjugular intrahepatic portosystemic shunt: current status. Gastroenterology 2003; 124: 1700-1710
25. Bureau C, Pagan JC, Layrargues GP, Metivier S, Bellot P, Perreault P, Otal P, Abraldes JG, Peron JM, Rousseau H, Bosch J, Vinel JP. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int 2007; 27: 742-747
26. Jung HS, Kalva SP, Greenfield AJ, Waltman AC, Walker TG, Athanasoulis CA, Wicky ST. TIPS: comparison of shunt patency and clinical outcomes between bare stents and expanded polytetrafluoroethylene stent-grafts. J Vasc Interv Radiol 2009; 20: 180-185
27. Rössle M, Siegerstetter V, Euringer W, Olschewski M, Kromeier J, Kurz K, Langer M. The use of a polytetrafluoroethylene-covered stent graft for transjugular intrahepatic portosystemic shunt (TIPS): Long-term follow-up of 100 patients. Acta Radiol 2006; 47: 660-666
28. Yang Z, Han G, Wu Q, Ye X, Jin Z, Yin Z, Qi X, Bai M, Wu K, Fan D. Patency and clinical outcomes of transjugular intrahepatic portosystemic shunt with polytetrafluoroethylenecovered stents versus bare stents: a meta-analysis. J Gastroenterol Hepatol 2010; 25: 1718-1725
29. Bureau C, Garcia-Pagan JC, Otal P, Pomier-Layrargues G, Chabbert V, Cortez C, Perreault P, Péron JM, Abraldes JG, Bouchard L, Bilbao JI, Bosch J, Rousseau H, Vinel JP. Improved clinical outcome using polytetrafluoroethylenecoated stents for TIPS: results of a randomized study. Gastroenterology 2004; 126: 469-475
30. Burroughs AK, Bosch J, Garcia-Tsao G, Henderson JM, Laine L, Nevens F, Riggio O. Definition of key events: Lets' s try again. In: De Franchis R, Baveno International Consensus Workshop. Portal hypertension III: Proceedings of the Third Baveno International Consensus Workshop on definitions, methodology and therapeutic strategie. Malden, MA: Blackwell Pub, 2000: 13-21
31. Arroyo V, Ginès P, Gerbes AL, Dudley FJ, Gentilini P, Laffi G, Reynolds TB, Ring-Larsen H, Schölmerich J. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23: 164-176
32. LaBerge JM, Ring EJ, Gordon RL, Lake JR, Doherty MM, Somberg KA, Roberts JP, Ascher NL. Creation of transjugular intrahepatic portosystemic shunts with the wallstent endoprosthesis: results in 100 patients. Radiology 1993; 187: 413-420
33. Sahagun G, Benner KG, Saxon R, Barton RE, Rabkin J, Keller FS, Rosch J. Outcome of 100 patients after transjugular intrahepatic portosystemic shunt for variceal hemorrhage. Am J Gastroenterol 1997; 92: 1444-1452
34. Biecker E, Roth F, Heller J, Schild HH, Sauerbruch T, Schepke M. Prognostic role of the initial portal pressure gradient reduction after TIPS in patients with cirrhosis. Eur J Gastroenterol Hepatol 2007; 19: 846-852
35. Wiesner R, Edwards E, Freeman R, Harper A, Kim R, Kamath P, Kremers W, Lake J, Howard T, Merion RM, Wolfe RA, Krom R. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96
36. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871
37. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, D'Amico G, Dickson ER, Kim WR. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470
38. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, Krom RA, Kim WR. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7: 567-580
39. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-649
40. Boyer TD, Haskal ZJ. The role of transjugular intrahepatic portosystemic shunt in the management of portal hypertension. Hepatology 2005; 41: 386-400
41. Riggio O, Ridola L, Lucidi C, Angeloni S. Emerging issues in the use of transjugular intrahepatic portosystemic shunt (TIPS) for management of portal hypertension: time to update the guidelines? Dig Liver Dis 2010; 42: 462-467
42. Rössle M, Gerbes AL. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010; 59: 988-1000
43. Rössle M, Grandt D. TIPS: an update. Best Pract Res Clin Gastroenterol 2004; 18: 99-123
44. Corrao G, Ferrari P, Zambon A, Torchio P. Are the recent trends in liver cirrhosis mortality affected by the changes in alcohol consumption? Analysis of latency period in European countries. J Stud Alcohol 1997; 58: 486-494
45. Scaglioni F, Ciccia S, Marino M, Bedogni G, Bellentani S. ASH and NASH. Dig Dis 2011; 29: 202-210
46. Clark TW. Management of shunt dysfunction in the era of TIPS endografts. Tech Vasc Interv Radiol 2008; 11: 212-216
47. Wu X, Ding W, Cao J, Han J, Huang Q, Li N, Li J. Favorable clinical outcome using a covered stent following transjugular intrahepatic portosystemic shunt in patients with portal hypertension. J Hepatobiliary Pancreat Sci 2010; 17: 701-708
48. Membreno F, Baez AL, Pandula R, Walser E, Lau DT. Differences in long-term survival after transjugular intrahepatic portosystemic shunt for refractory ascites and variceal bleed. J Gastroenterol Hepatol 2005; 20: 474-481
49. Rössle M, Siegerstetter V, Olschewski M, Ochs A, Berger E, Haag K. How much reduction in portal pressure is necessary to prevent variceal rebleeding? A longitudinal study in 225 patients with transjugular intrahepatic portosystemic shunts. Am J Gastroenterol 2001; 96: 3379-3383
50. Casado M, Bosch J, García-Pagán JC, Bru C, Bañares R, Bandi JC, Escorsell A, Rodríguez-Láiz JM, Gilabert R, Feu F, Schorlemer C, Echenagusia A, Rodés J. Clinical events after transjugular intrahepatic portosystemic shunt: correlation with hemodynamic findings. Gastroenterology 1998; 114: 1296-1303
51. Kurmis TP. Transjugular intrahepatic portosystemic shunt: an analysis of outcomes. ANZ J Surg 2009; 79: 745-749
52. Durand F, Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. J Hepatol 2005; 42 Suppl: S100-S107